US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 7.270
- +0.090+1.25%
Close Jul 26 16:00 ET
- 7.240
- -0.030-0.41%
Post 20:01 ET
384.31MMarket Cap-9693P/E (TTM)
7.440High6.950Low209.52KVolume7.360Open7.180Pre Close1.52MTurnover0.80%Turnover RatioLossP/E (Static)52.86MShares9.69052wk High3.13P/B189.61MFloat Cap1.93052wk Low--Dividend TTM26.08MShs Float14.710Historical High--Div YieldTTM6.83%Amplitude1.450Historical Low7.233Avg Price1Lot Size
TScan Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -24.08%-29.27M | 7.74%-61.36M | -48.44%-23.77M | 147.15%8.02M | -64.75%-22.02M | -17.21%-23.59M | -36.62%-66.5M | -11.34%-16.01M | -24.65%-17M | -24.93%-13.37M |
| Net income from continuing operations | -33.59%-30.14M | -34.73%-89.22M | -4.75%-19.61M | -41.56%-23M | -59.27%-24.05M | -39.66%-22.56M | -36.19%-66.22M | -31.85%-18.72M | -2.56%-16.25M | -41.44%-15.1M |
| Depreciation and amortization | -16.34%1.25M | 4.36%5.36M | -13.75%1.28M | 2.80%1.29M | 7.37%1.3M | 25.44%1.5M | 54.36%5.14M | 29.95%1.48M | 18.47%1.25M | 82.60%1.21M |
| Other non cash items | -7.01%199K | 191.15%757K | -52.78%102K | --223K | --218K | --214K | --260K | --216K | ---- | ---- |
| Change In working capital | 45.70%-2.11M | 272.10%17.61M | -2,082.39%-6.2M | 961.10%28.4M | -41.92%-711K | 36.81%-3.88M | -73.51%-10.23M | 86.51%-284K | -1,378.29%-3.3M | 57.90%-501K |
| -Change in prepaid assets | 121.61%255K | 340.24%985K | -102.46%-49K | 53.86%-694K | 140.33%2.91M | 43.97%-1.18M | 84.20%-410K | 350.23%1.99M | -83.86%-1.5M | 180.61%1.21M |
| -Change in payables and accrued expense | -263.31%-2.01M | 201.67%3.8M | -61.43%670K | 56.69%749K | 13.08%1.15M | 162.47%1.23M | -61.16%1.26M | 382.44%1.74M | -81.55%478K | -52.89%1.02M |
| -Change in other working capital | 91.06%-352K | 215.70%12.82M | -70.01%-6.82M | -57.66%-3.58M | 1,095.49%27.16M | -90.24%-3.94M | -69.29%-11.08M | -107.50%-4.01M | -49.97%-2.27M | -47.62%-2.73M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -24.08%-29.27M | 7.74%-61.36M | -48.44%-23.77M | 147.15%8.02M | -64.75%-22.02M | -17.21%-23.59M | -36.62%-66.5M | -11.34%-16.01M | -24.65%-17M | -24.93%-13.37M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 4,415.39%36.16M | -1,338.08%-60.76M | 238.93%1.91M | -14,384.43%-61.41M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M | 50.29%-424K | 51.68%-1.89M |
| Net PPE purchase and sale | 15.87%-705K | 25.54%-3.15M | 65.94%-469K | -234.67%-1.42M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M | 50.29%-424K | 51.68%-1.89M |
| Net investment purchase and sale | --36.87M | ---57.61M | --2.38M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 4,415.39%36.16M | -1,338.08%-60.76M | 238.93%1.91M | -14,384.43%-61.41M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M | 50.29%-424K | 51.68%-1.89M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 258K | 361.38%135.44M | -82.41%19K | -100.87%-252K | 437,564.52%135.68M | 0 | -84.52%29.36M | -10.00%108K | -67.85%29.13M | 104.52%31K |
| Net issuance payments of debt | ---- | --0 | --0 | ---- | ---- | ---- | --29.35M | --0 | ---- | ---- |
| Net common stock issuance | ---- | 21,876.17%42.41M | --0 | ---186K | ---- | ---- | -99.78%193K | --193K | --0 | ---- |
| Proceeds from stock option exercised by employees | --258K | 69,846.62%93.03M | 111.11%19K | -1,420.00%-66K | 300,145.16%93.08M | --0 | -54.30%133K | -92.50%9K | 400.00%5K | -50.00%31K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---324K | ---94K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --258K | 361.38%135.44M | -82.41%19K | -100.87%-252K | 437,564.52%135.68M | --0 | -84.52%29.36M | -10.00%108K | -67.85%29.13M | 104.52%31K |
| Net cash flow | ||||||||||
| Beginning cash position | 10.66%138.39M | -24.86%125.06M | 12.56%160.22M | 63.71%213.87M | -31.01%100.64M | -24.86%125.06M | 370.34%166.44M | -22.18%142.34M | 22.33%130.64M | 19.47%145.87M |
| Current changes in cash | 129.29%7.15M | 132.21%13.33M | -26.36%-21.83M | -558.42%-53.65M | 843.54%113.23M | -18.76%-24.43M | -131.57%-41.37M | -4.91%-17.28M | -84.62%11.7M | 0.49%-15.23M |
| End cash Position | 44.62%145.54M | 10.66%138.39M | 10.66%138.39M | 12.56%160.22M | 63.71%213.87M | -31.01%100.64M | -24.86%125.06M | -24.86%125.06M | -22.18%142.34M | 22.33%130.64M |
| Free cash flow | -22.71%-29.97M | 8.80%-64.5M | -39.39%-24.24M | 137.86%6.6M | -47.06%-22.44M | -18.25%-24.43M | -20.66%-70.73M | -4.80%-17.39M | -20.24%-17.43M | -4.39%-15.26M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg